Miroculus

MicroRNA-based diagnostics



Products

Growing evidence of the clinical validity and utility of microRNAs as biomarkers is guiding our product development.

Our first application is detection of gastric cancer, the third deadliest cancer in the world.

 


Gastric Cancer

Facts

Incidence Rate: Approximately 1,000,000 new cases per year worldwide

Mortality Rate: Approximately 800,000 people per year worldwide

71% of the cases occur in emerging economies

Highest prevalence: Latin America and Asia Pacific

5 year survival rate: 90% in stage 1, 70% in stage 2, 40% in stage 3 and 0% in stage 4

Screening increases gastric cancer diagnosis in early stage from 7% to 85%

Unmet Clinical Need

Current guidelines recommend endoscopy and a biopsy to obtain an accurate diagnosis for every symptomatic individual. However, on average 98 out of every 100 symptomatic individuals who undergo endoscopy do not have cancer.

Miroculus provides a test with a sufficiently high negative predictive value to enable healthcare providers better prioritize and focus the endoscopic examination.


Results


Miroculus, in collaboration with other institutions, has led a multi-center clinical study comprising different countries and 650 subjects undergoing endoscopy.

Using these data, we have preliminary results on a machine-learned model that classifies gastric cancer patients. The model works across different hospitals, and uses only the microRNA profiles of the subjects. We are currently working on performance improvements and independent cohort validation.



In collaboration with:

References

1.Cancer Research UK - Stomach cancer screening

2. Chaya Krishnamurthy, et al (2011). Endoscopic Findings in Patients Presenting with Dysphagia: Analysis of a National Endoscopy Database. DRS, ESSD and JSDR.

3.Globocan Estimated Cancer Incidence, Mortality and Prevalence in the world 2012

4. Yock Young Dan, et al (2005). Endoscopic Screening for Gastric Cancer. Clinical Gastroenterology and Hepatology Journal 2006;4:709 –716.

5. Centers for Disease Control and Prevention’s (CDC) and National Center for Health Statistics (NCHS) (2009).Health, United States

6. Dr Wai K Leung, MD, et al (2008). Screening for gastric cancer in Asia: current evidence and practice. The Lancet Oncology.

7. Lee KJ, et al (2006). Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer.

8. Oshima A, et al. (1986). Evaluation of a mass screening program for stomach cancer with a case-control study design. International Journal of Cancer.

9. Akira Fukao, et al (2006). The evaluation of screening for gastric cancer in miyagi prefecture, Japan: A population-based case-control study. International Journal of Cancer.

10. Nihon Shokakibyo Gakkai Zassh, et al (1995). Epidemiological evaluation of the protective effect for dying of stomach cancer by screening programme for stomach cancer with applying a method of case-control study.

11. Kui Son Choi, et al (2014). Screening for Gastric Cancer: The Usefulness of Endoscopy. Clin Endosc.

12. Lee YY, et al (2011). The current status of gastric cancer screening in Korea: report on the National Cancer Screening Programme. Asian Pac J Cancer Prev.